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Available online 30 August 2018Background:Obesity or overweight is related to worse outcomes in patients with atrial fibrillation (AF) following
catheter ablation (CA). The role of being underweight in relation to recurrent arrhythmias post AF ablation is less
certain. We conducted a retrospective study to investigate the association of body mass index (BMI) with ar-
rhythmia outcomes in AF patients undergoing CA.
Methods: In a cohort of 1410 AF patients (mean age 57.2± 11.6 years; 68% male) undergoing single CA, the as-
sociation between BMI and AF ablation outcome was analyzed using BMI as a continuous variable and by four
BMI categories (b18.5 kg/m2, 18.5-24 kg/m2, 25-29 kg/m2, and≥ 30 kg/m2).
Result:We observed a positive association between a cut off value of BMI and risk of AF recurrence post AF abla-
tion. BMI≥26.36 kg/m2 was related to more AF recurrence (c-statistic 0.55, 95%CI 0.51–0.58; P b 0.01) with 50%
increased risk of AF recurrence (HR 1.50, 95% CI 1.22–1.86; P b 0.01). Recurrence rates in the four BMI categories
were 33.3%, 23.2%, 27.2 and 41.8%, respectively (P b 0.01).
Kaplan-Meier analysis showed that BMI categories of b18.5 kg/m2 and≥ 30 kg/m2were all associatedwithmore
AF recurrence (P= 0.01). Both underweight (HR 1.85, 95%CI 1.12–3.08; P = 0.02) and obesity (HR 1.78, 95%CI
1.17–2.72; P= 0.01) significantly increased the risk of AF recurrence in a Cox proportional hazard model.
Conclusion: BMI had good predictive value for AF ablation outcomes with a cut off value of ≥26.36 kg/m2. Apart
from being obese/overweight, being underweight might also be a risk factor for AF recurrence post ablation.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Atrial fibrillation
Body mass index
Obesity
Underweight
Catheter ablation1. Introduction
Obesity/overweight has many adverse impacts on hemodynamics
and cardiovascular structure or function [1]. For example, obesity may
increase insulin resistance and the prevalence of hypertension, heart
failure, coronary heart disease, obstructive sleep apnea (OSA) and atrial
fibrillation (AF) is generally higher among obese compared to non-
obese individuals [1,2]. The association between obesity and AF has
attracted much attention. In the Framingham Heart Study, for example,
every unit of increase in body mass index (BMI) was associated with acular Sciences, University of
. This is an open access article under4–5% increase in AF risk [3]. Furthermore, increased BMI was related
to the development of persistent or permanent AF. The
mechanism(s) of AF promotion induced by obesity are multifactorial,
and have been related to endothelial dysfunction, increased systemic in-
flammation, a prothrombotic state, systolic and diastolic dysfunction,
increased pericardial fat leading to structural remodeling as atrial
stretch increase, atrial fibrosis and scar formation [4]. Obesity or over-
weight has been related to a worse ablation outcome in patients with
AF [5,6]. Indeed, weight management has modified arrhythmia out-
comes post AF ablation [7]; however, various studies have reported con-
tradictory results [8]. Being underweight is also a risk factor for new
onset AF [9] and has been related to worse cardiovascular outcomes
post catheter ablation (CA) [10]. In this study, we investigated the asso-
ciation between BMI and arrhythmia outcomes in a cohort of 1410 AF
patients undergoing single catheter ablation.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Obesity or overweight is related to worse outcomes in patients
with atrial fibrillation (AF) following catheter ablation (CA). The
role of being underweight in relation to recurrent arrhythmias
post AF ablation is less certain.
Added value of this study
We found that BMI of ≥26.36 kg/m2 increased the risk of AF recur-
rence post ablation by 50% relative to lower BMI; in addition,
being underweight was also associatedwith higher AF recurrence
rates. Thus, the impact of BMI on ablation outcome appears to
have a “U” shape relationship such that underweight or overweight
was related to the arrhythmia recurrence post CA in AF patients.
Implications of all the available evidence
There may be different influences of BMI on AF recurrence in dif-
ferent cohorts with unique cut off values. Further research should
identify population-specific optimal BMIs that would lead to im-
proved outcomes post CA.
H. Deng et al. / EBioMedicine 35 (2018) 40–452. Materials and methods
2.1. Ethics
The study protocol was approved by the Clinical Research Ethics
Committee of Guangdong General Hospital. All patient signed written
informed consent for the ablation procedure and follow up observation.
2.2. Study subjects
This retrospective study included 1410 consecutive symptomatic
adult patients (mean age 57.2 ± 11.6 years; 68% male) with non-
valvular AF who underwent single ablation procedure between June
2011 and August 2015 in Guangdong General Hospital. Baseline clinical
data were collected from patients' medical records and the hospital pa-
tient database.
Underweightwas defined as a BMI of b18.5 kg/m2,while overweight
and obesity were defined as a BMI of 24 kg/m2-29 kg/m2 and BMI≥ 30
kg/m2, respectively. Patients were categorized into four groups with
BMI ranges as follows: b18.5 kg/m2, 18.5-24 kg/m2, 25-29 kg/m2 and
≥ 30 kg/m2.
Paroxysmal AF (PAF) was defined as AF that terminated spontane-
ously or with intervention within 7 days, persistent AF (PeAF) as AF
not terminating spontaneously (usually lasting ≥7 days), and
longstanding PeAF (LSPeAF) as AF lasting N1 year [11]. The term “non-
paroxysmal” AF (NPAF) included PeAF and LSPeAF.
2.3. Ablation strategy
All patients received anticoagulation therapy and underwent an ab-
lation procedure according to the guideline recommendations [12]. Pre-
procedural transoesophageal echocardiography (TEE) or left atrial com-
puted tomography (CT) was used to exclude left atrial thrombi. Amio-
darone was discontinued for N1 month and other antiarrhythmic
drugs (AADs) were discontinued for≥5 half-lives before the procedure.
During the ablation procedure,modest sedationwith fentanylwas used.
Following the trans-septal puncture, intravenous infusion ofunfractionated heparin was initiated with the activated clotting time
(ACT) maintained between 250 and 350 s. Circumferential pulmonary
vein isolation (CPVI)was performed under the guidance of 3Dmapping
system (Carto2 or 3, Johnsons Med Company or Navi X Ensite Classic
and Velocity, St Jude Medical). A cryoballoon catheter (Biosense Web-
ster, Inc., Diamond Bar, California) was used to perform cryoballoon ab-
lation, as previously described [13]. Pharmaceutical (ibutilide or
aminodarone) or electrical cardioversion was performed when AF con-
tinued post ablation.
2.4. Follow-up
Patients were treated with oral anticoagulants and amiodarone or
propafenone within the first three months post ablation (the blanking
period). Thereafter, oral anticoagulation was continued in patients
with a CHA2DS2-VASc score of ≥2, while the AAD was continued in
those with an atrial arrhythmia. Follow up visits including physical ex-
amination, 12 lead ECG and 24-h Holter ECG were performed at dis-
charge, 1, 3, 6 months post ablation and every 6 months thereafter.
Patients were encouraged tomake contact in case of symptoms sugges-
tive of a cardiac arrhythmia and then additional ECG or 24-h Holter
monitoring was performed as needed. Patients without evidence of ar-
rhythmia recurrence were followed up for a minimum of 12 months.
Arrhythmia recurred post the first three month (blanking period) was
the study endpoint. The study endpoint might be late recurrence (b12
month) or very late recurrence (N12month).
2.5. Statistical analysis
Continuous variables were described as mean± standard deviation,
and categorical variables were presented as number and percentage.
The ANOVA least significant difference (LSD) test or Chi-square test
was used to compared difference among the BMI groups. Cox multivari-
ate regression analysis was used to determine the predictive ability of
clinical characteristics for AF recurrence. The area under receiver operat-
ing characteristic curve (AUC)was used to test the predictive probability
of BMI and its cut off value for AF recurrence. In addition to demographic
and clinical factors, Cox proportional-hazardsmodels were also adjusted
for BMI (categorized as under or above 26.36 kg/m2 cut-off value) to
evaluate the impact of BMI on ablation outcomes. Kaplan-Meier analysis
was used to test the difference in time-dependent outcome among the
BMI groups (b18.5 kg/m2, ≥18.5 kg/m2–24 kg/m2, 25 kg/m2-29 g/m2
and≥ 30 kg/m2). A two-sided P value of b0.05 was considered statisti-
cally significant. Analyses were performed using the SPSS software ver-
sion 20.0 (IBM Corporation, Armonk, NY, USA) and statistical software
R version 3.0.2 (R Core Team, 2013).
3. Results
Of 1410 AF patients (mean age 57.2 ± 11.6 years; 68% male) under-
going single catheter ablation, 960 (68.1%) were male. Patient clinical
characteristics in relation to BMI categories are shown in Table 1. During
a mean follow-up 20.7 ± 8.8 months, AF recurrence occurred in 365
(27.9%), including 203 with PAF (18.6%) and 162 with NPAF (50.5%).
AF recurrence occurred in 33.3%, 23.2%, 27.2% and 41.8% of patients
with a BMI of b18.5 kg/m2, 18.5-24 kg/m2, 25-29 kg/m2 and ≥30 kg/
m2, respectively (P b 0.01) showing a “U” shaped pattern (see Fig. 4).
As shown in Table 1, patients with higher BMI values were younger,
more often male and more likely to have persistent/longstanding AF,
prior cardioversion, hypertension or larger left atrial size (all p b 0.01).
The underweight and obesity groups had higher serum BNP and re-
quired significantly more substrate ablations compared to other two
groups (all P b 0.01).
Onmultivariable Cox regression analysis, age, AF types, BMI, conges-
tive heart failure (CHF), left atrial diameter (LAD), glomerular filtration
rate (eGFR) and early recurrence (ER) (all P b 0.01) were significantly
Table 2
Multivariate analysis of risk factors for AF recurrence post ablation.
bRisk factor Hazard Ratioa (95% confidence interval) P value
Age 0.97(0.96–0.98) b0.01
AF types 1.78(1.42–2.23) b0.01
ER 3.77(3.02–4.72) b0.01
CHF 1.33(1.13–1.57) b0.01
LAD(mm) 1.07(1.04–1.09) b0.01
eGFR(ml/min/1.73m2) 0.97(0.96–0.97) b0.01
BMI(kg/m2) 1.06(0.98–1.10) 0.066
ER, early recurrence; CHF, prior history of contractive heart failure; LAD, left atrial diame-
ter; eGFR, estimated glomerular filtration rate; BMI, body mass index.
a Covariate categorical Cox regression analysis, forward conditional method, P b 0.05
means statistical significant.
b Adjusted by age, gender, bundle branch block, AF duration, chronic obstructive pul-
monary disease, alcohol consumption, smoking, hypertension, diabetes mellitus, stroke/
transient ischemic attack, coronary artery disease, ejection fraction and vascular disease,
early recurrence, left atrial size, and AF type.
42 H. Deng et al. / EBioMedicine 35 (2018) 40–45associated with AF recurrence (see Table 2). BMI was not an indepen-
dent risk factor for AF recurrence, with a non-significant trend (Hazard
Ratio [HR] 1.06, 95% Confidence Interval [CI] 0.98–1.10, P = 0.066). Re-
ceiver operating characteristic (ROC) curve analysis yielded a cut off
BMI value of 26.36 kg/m2 for AF recurrence (specificity 72.4%, sensitivity
37.2%). The area under curve (AUC) for BMI for recurrence prediction
(categorized as under or above 26.36 kg/m2 cut-off value) was 0.549
(95%CI 0.51–0.58; P b 0.01) (see Fig. 1).
Patientswith a BMI of≥26.36 kg/m2 had higher recurrence rate (P b
0.01), with larger LAD (P b 0.01) and lower eGFR (P b 0.01), as well as
higher prevalence of NPAF (P b 0.01), hypertension (P b 0.01) and dia-
betes mellitus (P = 0.026) at baseline, and more substrate ablations
and cardioversion during the procedure (see supplementary Table w1).
On a Cox multivariate regression analysis, patients with a BMI of
≥26.36 kg/m2 had a 50% increased risk of AF recurrence (HR 1.50, 95%
CI 1.22–1.86, P b 0.01) relative to those with lower BMI (see Table 3).
Kaplan-Meier analysis showed that patients with a BMI of ≥26.36 kg/
m2 had more arrhythmias compared to those with a BMI of b26.36 kg/
m2 (Log Rank, P b 0.01) during follow-up (see Fig. 2).
Kaplan-Meier analysis showed that BMI b 18.5 kg/m2 or≥ 30 kg/m2
with significantly more AF recurrence rates post-ablation (P = 0.011)
(see Fig. 3). Using a Cox proportional hazards model, BMI b 18.5 kg/m2
or ≥ 30 kg/m2 significantly increased the risk of AF recurrence (P b
0.05) (see Table 4).
4. Discussion
In this large cohort of AF patients undergoing CA, our principal find-
ings are as follows: (i) A BMI of ≥26.36 kg/m2 increased the risk of AFTable 1
Characteristics differences among groups with four BMI categories.
Characteristics Total Group 1 Gr
N (%) 1410 (100) 48 (3.4) 73
Age, years 57.3 ± 11.5 57 ± 15.7⁎ 58
Male 960 (68.1) 21 (43.8) 44
Recurrence 365 (25.9) 16 (33.3)† 17
LAD,mm 36.9 ± 5.3 33.5 ± 4.9⁎ 35
BNP, pg/ml 319 ± 465 481 ± 668† 30
CRP, mg/dl 2.3 ± 3.8 2.3 ± 2.3 2.2
eGFR, ml/min/1.73m2 87 ± 22 91 ± 27 88
EF, % 64.7 ± 6.1 66 ± 5.3 64
Fu, months 20.7 ± 8.8 20.2 ± 8.4 20
PeAF 320 (22.7) 7 (14.6)⁎ 14
BBB 94 (6.6) 5 (10.4) 51
COPD 9 (0.6) 1 (2.1) 5 (
Alchohol 75 (5.3) 0 28
Smoking 244 (17.3) 4 (8.3) 11
HF 71 (5) 1 (2.1) 30
Hypertension 508 (36.1) 10 (20.8)⁎ 24
DM 143 (10.2) 3 (6.2) 70
Stroke 84 (6) 3 (6.2) 47
CAD 105 (7.5) 2 (4.2) 53
Cryoballoon 74 (5.3) 6 (12.6) 38
Smart touch 247 (17.5) 5(10.4) 13
ECV 157 (11.2) 3 (6.2)⁎ 57
Pharm CV 221 (15.7) 8 (16.7) 99
CPVI 1394(99.3) 46(95.8) 72
CFAE 35 (2.9) 3 (6.2)⁎ 23
CTI 337 (24) 14 (29.2)† 15
SCVI 87(6.2) 2(4.2) 49
Linear 266 (18.9) 12 (25)† 11
ER 317 (22.5) 9 (18.8) 16
Values are n (%) or mean± SD. Chi-square test or ANOVA LSD test.
Group1, BMI b 18.5 kg/m2; Group 2, BMI 18.5-24 kg/m2; Group 3, BMI25-29 kg/m2; Group 4, B
BBB, bundle branch block; BMI, body mass index; BNP, B-type natriuretic peptide; CAD, corona
cuspid isthmus ablation; CFAE, complex fractionated atrial electrogram ablation; COPD, chronic
betesmellitus; ECV, electrical cardioversion; ER, early recurrence; EF, ejection fraction; eGFR, est
LAD, left atrial diameter; Linear, linear ablation; PVI, pulmonary vein isolation; Pharm CV, pharm
ST, smart touch ablation catheter.
⁎ p b 0.05 vs. other groups.
† p b 0.05 vs. group 2 or 3.recurrence post ablation by 50% relative to lower BMI; and (ii) being un-
derweight was also associated with higher AF recurrence rates. The im-
pact of BMI on ablation outcome appears to have a “U” shape.
Regardless of ethnicity, overweight/obesity has been reported as an
independent risk factor for new onset AF, being associated with a 20%
higher risk of AF compared to normal weight [14] [15]. Obesity has
also been associated with higher risk of post-operative AF [10] and AF
recurrences post CA of AF [16]. In the study byWinkle et al. [17], for ex-
ample, among 2715 consecutive patients undergoing single or repeated
ablation for symptomatic AF, a BMI of ≥35 kg/m2 impacted on ablation
outcomes was reported. Our study found a lower BMI cut off valueoup 2 Group 3 Group 4 P value
7 (52.3) 570 (40.4) 55(3.9) (40.4) P value
.5 ± 11.8 55.7 ± 10.8 55.3 ± 11.6 b0.01
6 (33) 435 (30.9) 38 (69.1) b0.01
1 (23.2) 155 (27.2) 23 (41.8)⁎ b0.01
.7 ± 5.0 38.2 ± 5.2 40.8 ± 5.5 b0.01
8 ± 454 306 ± 444 473 ± 568† b0.01
± 3.3 2.5 ± 4.4 2.8 ± 2.9 0.39
± 24 86 ± 19 83 ± 25 0.054
.8 ± 6.3 64.6 ± 5.8 63.5 ± 7.3 0.22
.8 ± 8.6 20.8 ± 9.2 18.2 ± 7.3 0.82
0 (19.0) 155 (27.2) 19 (34.5) b0.01
(6.9) 31 (5.4) 7 (12.7) 0.12
0.7) 3 (0.5) 0 0.56
(3.8) 44 (7.7)⁎ 3 (5.5) b0.01
7 (15.9) 116 (20.4)⁎ 7 (12.7) 0.04
(4.1) 34 (6) 6 (10.9) 0.22
8 (33.7) 221 (38.8) 29 (52.7) b0.01
(9.5) 61 (10.7) 9 (16.4) 0.30
(6.4) 31 (5.4) 3 (5.5) 0.99
(7.2) 45 (7.9) 5 (9.1) 0.75
(5.2) 28 (4.9) 2 (3.6) 0.14
1 (17.8) 96 (16.8) 15 (27.3) 0.14
(7.8) 83 (14.6) 14 (25.9) b0.01
(13.4) 100 (17.5) 14 (25.5)⁎ 0.04
6(98.8) 568(99.6) 54(98.1) 0.91
(3.1) 7 (1.2) 2 (3.6) 0.045
7 (21.3) 144 (25.3) 22 (40)⁎ b0.01
(6.6) 33(5.8) 3 (5.6) 0.85
2 (15.2) 125 (21.9) 17 (30.9)⁎ 0.001
4 (22.3) 128 (22.5) 16 (29.1) 0.62
MI≥ 30 kg/m2;
ry artery disease; Cryoballoon, cryoballoon ablation; CRP, C reactive protein; CTI, cavo-tri-
obstructive pulmonary disease; CPVI, circumferential pulmonary vein isolation; DM, dia-
imated glomerularfiltration rate; HF, history of congestive heart failure; HT, hypertension;
aceutical cardioversion; TIA, transient ischemic attack; SCVI, superior vena cava ablation;
Fig. 1. Predictive ability analysis for AF recurrence post-catheter ablation in relation to BMI
≥26.36 kg/m2. AUC, area under curve; ROC, receiver operating characteristic; BMI, body
mass index. Red line, BMI ≥26.36 kg/m2; black line, BMI b26.36 kg/m2. Fig. 2.Kaplan-Meier curve of freedom fromAT/AFL in patients with BMI under or≥ 26.36
kg/m2. BMI, body mass index; AT/AFL, atrial tachycardia, atrial flutter or fibrillation. Log
Rank test, statistical significant when P b 0.05.
H. Deng et al. / EBioMedicine 35 (2018) 40–45(26.36 kg/m2) and we also divided patients into four groups based on
accepted definitions of underweight, normal weight, overweight and
obesity. Nevertheless, the proportion of obese patients in our cohort
was small (3.9%) while there were 39% patients with BMI ≥30 kg/m2
in the cohort by Winkle et al. [17].
Weight management provides more evidence of the association be-
tween obesity and AF. In the LEGACY Study [7], weight management
was offered to patients with a BMI of≥27 kg/m2 and an average weight
loss of≥10%was associatedwith over 6-fold increase in arrhythmia free
survival. The result of the ARREST-AF study also showed that weight
loss in AF patients with a BMI of ≥27 kg/m2 improved the long-term
outcome irrespective of single or multiple ablations [6]. The managed
weight of these two studies was closed to findings in the present
study (26.36 kg/m2).
The role obesity plays in the initiation and maintaining of AF is un-
clear. Obesity increases the percentage of epicardial adipose tissue
(EAT) and increasing EAT might result in more extensive fatty infiltra-
tion in the myocardium leading to fibrosis or electrical remodeling
[18]. Apart fromobesity being related to left size enlargement and fibro-
sis, atrial inflammation and lipid infiltration, changes in atrialTable 3
Multivariate analysis for AF Recurrence According to the cut off value of BMI.
bRisk factor Hazard Ratioa (95% confidence interval) P value
Age 1.17(0.93–1.48) 0.18
CHF 1.43(1.27–1.61) b0.01
Stroke/TIA 1.24(1.03–1.50) 0.02
BMI
c b26.36 kg/m2 1.00
≥26.36 kg/m2 1.50(1.22–1.86) b0.01
a Covariate categorical Cox regression analysis, forward conditional method, P b 0.05
means statistical significant.
b Adjusted by gender, age, bundle branch block, AF duration, ejection fraction, presence
of coronary artery disease, heart failure, hypertension, diabetes mellitus, vascular disease,
stroke or transient ischemic attack, bundle branch block, chronic obstructive pulmonary
disease, alcohol consumption, and smoking.
c Reference group.electrophysiological properties have been observed in both animals
and humans [19] [20] [21]. In our cohort, patients with obesity/over-
weight had larger left atrial size and required more additional ablationFig. 3. Kaplan-Meier curve of four BMI categories. BMI, body mass index; AT/AFL, AT/AFL,
atrial tachycardia, atrial flutter or fibrillation. BMI categories: black line, BMI b18.5 kg/m2;
green line, BMI 18.5 kg/m2–24 kg/m2; blue line, BMI 25-29 kg/m2; red line, BMI ≥30 kg/
m2. Log Rank test, statistical significant when P b 0.05.
Table 4
Proportional Hazards of BMI categories for AF recurrence.
bRisk factor Hazard Ratioa (95% confidence interval) P value
BMI cat1 1.85(1.12–3.08) 0.02
BMI cat4 1.78(1.17–2.72) 0.01
age 1.02(1.00–1.02) 0.01
AF type 1.79(1.43–2.25) b0.01
CHF 1.36(1.17–1.59) b0.01
LAD 1.06(1.04–1.08) b0.01
ER 4.48(3.59–5.59) b0.01
BMI, bodymass index; CHF, prior history of contractive heart failure; LAD, left atrial diam-
eter; ER, early recurrence.
a Covariate categorical Cox regression analysis, forward conditional method, P b 0.05
means statistical significant.
b Adjusted by gender, bundle branch block, AF duration, chronic obstructive pulmonary
disease, alcohol consumption, smoking, hypertension, diabetes mellitus, stroke/transient
ischemic attack, coronary artery disease, ejection fraction and vascular disease, early re-
currence, left atrial size, AF type and BMI categories (cat 1, BMI b 18.5 kg/m2;c cat 2, BMI
18.5-24 kg/m2; cat 3, BMI25-29 kg/m2; cat 4, BMI≥ 30 kg/m2).
c Reference group.
44 H. Deng et al. / EBioMedicine 35 (2018) 40–45or cardioversion during the procedure, which implies the presence of a
more complicated AF substrate.
In a large observational Asian cohort, incident AF risk was increased
in underweight, overweight and obesity individuals by 21%, 14% and
52%, when compared to those with normal weight; also, for those
with normal weight, abdominal obesity was found an important risk
factor for AF [22]. In a study of elderly outpatients with AF, being under-
weight has been related to worse outcomes [23]. In a report from a Ko-
rean nationwide population- based study, being underweight increased
risk of AF onset by 13%, while obesity increased risk by 26%, suggesting a
U-shape relationship of BMI and AF [9].
The association of underweight and AF recurrence post ablation has
not been previously reported. In a study by Bunch et al. [24], under-
weight was defined as BMI ≤20 kg/m2 but did not increase the recur-
rent risk post-CA, although those who were underweight experienced
more cardiovascular events including stroke despite less AF burden.
5. Limitations
This is a single centre retrospective observational study. Arrhythmia
outcome was acquired based on the clinical symptoms, 12-lead ECG or
24-h ECG recording and symptom driving ECG. Some asymptomatic
AF recurrencesmight bemissed by the follow-up tools we used, and ab-
lation techniques and methods may have evolved during the study pe-
riod. We have focused on evaluation of the predictive ability of clinical
factors prior to a CA decision, and our objective was not to compareFig. 4. Plot relationship between BMI categories and AF recurrence.one catheter or ablation method to another in this ‘real world’ observa-
tional cohort. The relatively small number of patients in the under-
weight category is another limitation. Finally, our results were derived
from a Chinese cohort with mean age b 60 years old and may not be
generalizable to individuals with advanced age or a different ethnicity.
In conclusion, BMI had good predictive value of ablation outcome
with a cut off value ≥26.36 kg/m2. Apart from obesity/overweight,
being underweight might also be another risk factor of AF recurrence
post ablation.
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